Mohammad Sadeq Khosravy

Mohammad Sadeq Khosravy

Auto-generated profile, based on publicly available information

Mohammad Sadeq Khosravy

WHO Collaborating Centre for Reference and Research on Rabies Pasteur Institute of Iran Tehran Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
FKFarnaz Khodabakhsh
Farnaz Khodabakhsh
MSMorteza Salimian
Morteza Salimian
AMArdavan Mehdizadeh
Ardavan Mehdizadeh
MKMohammad Sadeq Khosravy
Mohammad Sadeq Khosravy
AVAlireza Vafabakhsh
Alireza Vafabakhsh
RCReza Ahangari Cohan
Reza Ahangari Cohan
Therapeutic fragmented antibodies show a poor pharmacokinetic profile that leads to frequent high-dose administration. In the current study, for the first time, a novel proline, alanine, serine (PAS) repeat sequence, called PAS#208, was designed to extend the plasma half-life of a nano-sized anti-Vascular Endothelial Growth Factor-A single-domain antibody. Polyacrylamide gel electrophoresis, circular dichroism, dynamic light scattering, and electrophoretic light scattering were used to assess the physicochemical properties of the newly designed PAS sequence. The effect of PAS#208 on the biological activity of a single-domain antibody was studied using an in vitro proliferation assay. The pharmacokinetic parameters including terminal half-life, the volume of distribution, elimination rate constant, and clearance were determined in mice model and compared to the native protein and PAS#1(200) sequence. The novel PAS repeat sequence showed comparable physicochemical, biological, and pharmacokinetic features to the previously reported PAS#1(200) sequence. The PAS#208 increased the hydrodynamic radius and decreased significantly the electrophoretic mobility of the native protein without any change in zeta potential. Surprisingly, the fusion of PAS#208 to the single-domain antibody increased the binding potency. In addition, it did not alter the biological activity and did not show any cytotoxicity on the normal cells. The PAS#208 sequence improved the terminal half-life (14-fold) as well as other pharmacokinetic parameters significantly. The simplicity as well as superior effects on half-life extension, make PAS#208 sequence as a novel sequence for in vivo pharmacokinetic enhancement of therapeutic fragmented antibodies. Significance Statement •In the current study, a new PAS sequence was developed that showed comparable physicochemical, biological, and pharmacokinetic features to the previously reported PAS#1(200) sequence. •The simplicity as well as superior effects on half-life extension, make PAS#208 sequence as a novel sequence for in vivo pharmacokinetic enhancement of recombinant small proteins.

29 December 2023 in Epidemiology and Health System Journal
Verified
Journal Article
Open access
PDF file
NSNazanin Shabansalmani
Nazanin Shabansalmani
BPBehzad Pourhoseein
Behzad Pourhoseein
MKMohammadsadeq Khosravy
Mohammadsadeq Khosravy
FFFirouzeh Farahtaj
Firouzeh Farahtaj
MFMaryam Fazeli
Maryam Fazeli
RBRouzbeh Bashar
Rouzbeh Bashar
Rabies virus is responsible for 60000 deaths annually worldwide, and over 95% of all human rabies deaths occur in developing countries. In Iran, the annual number of animal bites is 180 per 100000 people, and rabies control programs focus more on post-exposure prophylaxis (PEP). In this study, the data on people whose death was caused by rabies were obtained from the WHO Collaborating Center (CC) for Reference and Research on Rabies (Pasteur Institute of Iran) from 2011 to 2022. Data analysis showed a remarkable increase in human rabies mortality rate after 10 years in Iran in 2022, with 14 cases. Then, the causes were investigated despite prevention measures. The increase in human rabies cases in Iran indicates that the currently used control methods are insufficient. Controlling the population of stray dogs, sterilization, and vaccination coverage of 70% are the most essential and basic steps in preventing rabies.

24 June 2024 in Veterinary Medicine and Science
Verified
Journal Article
Open access
MFMehdi Fazlalipour
Mehdi Fazlalipour
NSNazanin Shabansalmani
Nazanin Shabansalmani
FFFirouzeh Farahtaj
Firouzeh Farahtaj
SMSiamak Massoudi
Siamak Massoudi
MKMohammad Sadegh Khosravy
Mohammad Sadegh Khosravy
RBRouzbeh Bashar
Rouzbeh Bashar
Rabies is a fatal and zoonotic disease that remains endemic in Iran. In this article, rabies in a striped hyena (Hyaena hyaena) in Qazvin Province, Iran, was found when being hunted for using the genitals for traditional thoughts of the people. The fluorescent antibody technique confirmed rabies infection in the brain sample, and vaccination was done for injured hunter.

17 January 2023 in Pathogens and Disease
Verified
Journal Article
Closed access
PDF file
GBGolnaz Bahramali
Golnaz Bahramali
MSMaryam Mashhadi Abolghasem Shirazi
Maryam Mashhadi Abolghasem Shirazi
MHMina Hannan
Mina Hannan
MAMohammad Reza Aghasadeghi
Mohammad Reza Aghasadeghi
MKMohammad Sadeq Khosravy
Mohammad Sadeq Khosravy
SSSeyed Mehdi Sadat
Seyed Mehdi Sadat
The coronavirus disease (COVID-19) pandemic has imposed deployment of an effective vaccine as a worldwide health priority. The new variants of SARS-CoV-2 have also brought serious concerns due to virus eradiation hesitancy. In this study, we evaluated the protective immune system activity of a recombinant viral vector-based vaccine candidate encoding a fusion spike, membrane and nucleocapsid proteins, Spike (528–1273aa)-M-N, in BALB/c via two different routes of delivery, intranasal and subcutaneous. The immune responses were then assessed through specific SARS-CoV-2 antibodies, interleukin and granzyme B secretion. The outcomes showed that the IgG titer and IgA secretion was higher in intranasal route in comparison with the subcutaneous, and what is more, a higher titer of IL-4 was detected through the intranasal route, whereas IFN-γ was highly induced via the subcutaneous route. The cytotoxic cell activities were mostly achieved via subcutaneous route immunization. Vaccination with the target antigen is immunogenic and led to induction of specific antibodies. Both humoral and cellular immunity arms were well activated in immunized mice, especially through intranasal route with detectable IgA and IgG. Therefore, implication of the platform as a potential vaccine candidate has potential as a future prophylactic vaccine that guarantees further investigations for the assessment of its immunogenicity in humans.